• Brand Name - Thiomed
  • Innovator Brand Name - Tepadina
  • API - Thiotepa
  • Packaging - Single-use vial
  • Strength - 15 mg, 100 mg
  • Manufacturer Name - Mediclone


It is an alkylating agent indicated for the treatment of: 

  • Adenocarcinoma of the Breast or Ovary. 
  • Malignant Effusions: to manage the intracavitary effusions in order to diffuse or localized neoplastic diseases of the numerous serosal cavities.
  • Superficial Papillary Carcinoma of the Urinary Bladder.
  • Class 3 Beta-Thalassemia: for reducing and resisting the risk of the graft rejection when recommended to used in conjunction with the higher dose of the busulfan and cyclophosphamide as the preparative regimen for the allogeneic HSCT for the patients who are pediatric with the class 3 beta-thalassemia.
Thiotepa Dosage

Thiotepa dosage should be taken intravenously under an experienced healthcare provider.

Thiotepa side effects

The common side effects of thiotepa include vomiting, abdominal pain, nausea, anorexia, fatigue, rash, weakness, urticaria, laryngeal edema, anaphylactic shock, asthma, wheezing, contact dermatitis, pain at the injection site, vision dizziness, blurred vision, headache, dysuria, urinary retention, chemical cystitis, amenorrhea, conjunctivitis and interference with the spermatogenesis.

Warnings and Precautions
  • Do not administer live or attenuated viral or bacterial vaccines to a patient treated with this medication until the immunosuppressive effects have resolved.
  • Treatment with this drug can be responsible for skin discoloration, blistering, desquamation, pruritus and peeling that could be severe in the groin, skin folds, axillae in the neck area, and under dressings.
  • Instruct patients to shower or bathe with the water at least a couple of times daily through 48 hours after the administration of this drug.
  • Patients must be monitored for the serum transaminases and bilirubin daily through BMT Day +28, and provide supportive care to patients who develop hepatic veno-occlusive disease.
  • Febrile reactions and discharge from a subcutaneous lesion can occur as the result of the breakdown of the tumor tissue.
  • Patients must be informed about developing low blood cell counts and required for a hematopoietic progenitor cell infusion.
  • In some patients prolonged apnea occurred when succinylcholine was administered before surgery, following combined use of the thiotepa 15 mg and other anticancer agents.
  • Patients must be instructed in order to report to their doctor in the event of the bleeding or fever.
  • Counsel patients on the symptoms of hypersensitivity and to seek emergency help if they experience any of these symptoms.
  • Advise males with the female sexual partners about reproductive potential in order to use effective contraception during the treatment with this drug and for at least 12 months after the final dose of the Thiotepa.
  • It may cause fetal harm. Females taking this medicine must be instructed in order to avoid pregnancy while on the treatment with Thiotepa and for minimum six months after the final dose of it.
  • Females should be advised to report pregnancy as soon as possible.
  • Patients should be instructed that this medicine may produce infertility. Male patients must be informed about the possibility of the sperm conservation prior to the initiation of the therapy.
  • Advise patients to avoid breastfeeding while receiving this medication.
  • Inform patients that this medicine may increase the risk of secondary malignancy.
Supplied/Storage and handling

Care should be exercised in the handling of THIOTEPA. Vials should not be opened or crushed. Store permitted between 2°C to 8°C (36° to 46°F). Do not freeze it.

Drug interaction of thiotepa
  • In vitro studies suggest that thiotepa is metabolized by CYP3A4 and CYP2B6 to its active metabolite TEPA. Avoid coadministration of strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with thiotepa due to the potential effects on efficacy as well as toxicity. Consider alternative drugs with no or minimal potential to inhibit or induce CYP3A4. If concomitant use of strong CYP3A4 modulators cannot be avoided, monitor for adverse drug reactions.
  • Use of thiotepa together with cyclophosphamide in patients decreases the conversion of cyclophosphamide to the active metabolite, 4-hydroxycyclophosphamide; the effect seems sequence-dependent with a greater decrement in the conversion to 4-hydroxycyclophosphamide when thiotepa is used 1.5 hours prior to the intravenous use of cyclophosphamide in comparison with the administration of thiotepa following intravenous cyclophosphamide. The decrease in the level of 4-hydroxycyclophosphamide may potentially decrease the efficacy of cyclophosphamide treatment.

Commonly asked questions:

Thiotepa is a cytotoxic agent. The radiomimetic action of thiotepa is believed to occur through the release of ethyleneimine radicals which, like irradiation, disrupt the bonds of DNA.

Thiotepa is basically an alkylating agent.

The active ingredient in the medicine is Thiotepa and the inactive ingredient is water for injection.

In an event of overdose, patients may experience most important adverse reactions: myeloablation and pancytopenia.

Hypersensitivity to the active substance and Concomitant use with live or attenuated vaccines.

It is also used in the palliation of many neoplastic diseases. The best outcomes are found in the treatment of adenocarcinoma of the ovary and breast, papillary thyroid cancer and bladder cancer. It is recommended to control the intracavitary effusions caused by the serosal neoplastic deposits.

  • You can buy thiotepa 15 mg or thiotepa 100 mg from any authorized whole seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole seller/supplier/exporter before buying the product.
  • The buyer should check the existing law in their home country before importing the product.

Patients can simply fill the order form or can send mail at Patient can also send WhatsApp message to +91 8130290915. We will reply ASAP with the details of Pricing and procedure.
Note:- The order will be confirmed only after the receipt of Valid prescription of Clinician

Store the medicine Thiotepa at temperature 2°C to 8°C (36° to 46°F).
Do not freeze the medicine.


All Trademark and Brand that appear on the website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. Thiotepa Injection is a pharmaceutical drug that legally requires a medical prescription to be dispensed.

Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller and Pharmacies.